H.C. Wainwright analyst Swayampakula Ramakanth upgraded Aveo Pharmaceuticals to Buy from Neutral and raised his price target for the shares to $1.75 from $1.00. The company yesterday provided an update from the ongoing Phase 3 Tivo-3 study of tivozanib for the treatment of advanced renal cell carcinoma that showed an improved overall survival hazard ratio of 0.99 compared to 1.12 reported back in February, Ramakanth tells investors in a research note. The analyst is encouraged and believes tivozanib could back on track for U.S. regulatory approval in 2021.